TY - JOUR
T1 - Improved Structure and Function in Early-Detected Second-Eye Neovascular Age-Related Macular Degeneration
T2 - FASBAT/Early Detection of Neovascular Age-Related Macular Degeneration Report 1
AU - FASBAT Study Group
AU - Gale, Richard P
AU - Airody, Archana
AU - Sivaprasad, Sobha
AU - Hanson, Rachel L W
AU - Allgar, Victoria
AU - McKibbin, Martin
AU - Morland, Antony B
AU - Peto, Tunde
AU - Porteous, Mia
AU - Chakravarthy, Usha
N1 - Copyright © 2023 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
PY - 2024/6
Y1 - 2024/6
N2 - PURPOSE: Visual acuity (VA) and structural biomarker assessment before and 24-months after early detection and routine treatment of second-eye involvement with neovascular age-related macular degeneration (nAMD) and additional comparison with the first eye affected.DESIGN: Prospective, 22-center observational study of participants with unilateral nAMD in the Early Detection of Neovascular AMD (EDNA) study, coenrolled into the Observing Fibrosis, Macular Atrophy and Subretinal Highly Reflective Material, Before and After Intervention with anti-VEGF Treatment (FASBAT) study for an additional 2-year follow-up.PARTICIPANTS: Older adults (> 50 years) with new onset nAMD in the first eye.METHODS: Assessment of both eyes with OCT, color fundus photography (CFP), clinic-measured VA, and quality of life (QoL).MAIN OUTCOME MEASURES: Prevalence of atrophy, subretinal hyperreflective material (SHRM), intraretinal fluid (IRF), subretinal fluid (SRF), and changes in VA over the study duration in both the first and second eyes affected with nAMD. Composite QoL scores over time.RESULTS: Of 431 participants recruited to the FASBAT study, the second eye converted to nAMD in 100 participants at a mean of 18.9 months. Visual acuity was 18 letters better at the time of early diagnosis in the second eye compared with conventional diagnosis in the first eye (72.9 vs. 55.6 letters). Visual acuity remained better in the second eye 24.9 months postconversion, at 69.5 letters compared with 59.7 letters at a similar matched time point in the first eye (18.9 months). A greater proportion of participants had vision > 70 letters in the second eye versus the first eye, 24.9 months postconversion (61 vs. 35). Prevalence of SHRM and IRF was lower in the second eye compared with the first eye 24.9 months postconversion. However, SRF prevalence was greater in the second eye 24.9 months postconversion. The development and progression of total area of atrophy appears similar in both eyes. Mean composite QoL scores increased over time, with a significant correlation between VA for the second eye only 24.9 months postconversion.CONCLUSION: This study has shown that early detection of exudative AMD in the second eye is associated with reduced prevalence of SHRM and IRF and greater VA, which is significantly correlated with maintained QoL.FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
AB - PURPOSE: Visual acuity (VA) and structural biomarker assessment before and 24-months after early detection and routine treatment of second-eye involvement with neovascular age-related macular degeneration (nAMD) and additional comparison with the first eye affected.DESIGN: Prospective, 22-center observational study of participants with unilateral nAMD in the Early Detection of Neovascular AMD (EDNA) study, coenrolled into the Observing Fibrosis, Macular Atrophy and Subretinal Highly Reflective Material, Before and After Intervention with anti-VEGF Treatment (FASBAT) study for an additional 2-year follow-up.PARTICIPANTS: Older adults (> 50 years) with new onset nAMD in the first eye.METHODS: Assessment of both eyes with OCT, color fundus photography (CFP), clinic-measured VA, and quality of life (QoL).MAIN OUTCOME MEASURES: Prevalence of atrophy, subretinal hyperreflective material (SHRM), intraretinal fluid (IRF), subretinal fluid (SRF), and changes in VA over the study duration in both the first and second eyes affected with nAMD. Composite QoL scores over time.RESULTS: Of 431 participants recruited to the FASBAT study, the second eye converted to nAMD in 100 participants at a mean of 18.9 months. Visual acuity was 18 letters better at the time of early diagnosis in the second eye compared with conventional diagnosis in the first eye (72.9 vs. 55.6 letters). Visual acuity remained better in the second eye 24.9 months postconversion, at 69.5 letters compared with 59.7 letters at a similar matched time point in the first eye (18.9 months). A greater proportion of participants had vision > 70 letters in the second eye versus the first eye, 24.9 months postconversion (61 vs. 35). Prevalence of SHRM and IRF was lower in the second eye compared with the first eye 24.9 months postconversion. However, SRF prevalence was greater in the second eye 24.9 months postconversion. The development and progression of total area of atrophy appears similar in both eyes. Mean composite QoL scores increased over time, with a significant correlation between VA for the second eye only 24.9 months postconversion.CONCLUSION: This study has shown that early detection of exudative AMD in the second eye is associated with reduced prevalence of SHRM and IRF and greater VA, which is significantly correlated with maintained QoL.FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
KW - Humans
KW - Prospective Studies
KW - Male
KW - Female
KW - Visual Acuity
KW - Aged
KW - Tomography, Optical Coherence/methods
KW - Wet Macular Degeneration/diagnosis
KW - Early Diagnosis
KW - Fluorescein Angiography/methods
KW - Follow-Up Studies
KW - Quality of Life
KW - Middle Aged
KW - Angiogenesis Inhibitors/administration & dosage
KW - Fundus Oculi
KW - Intravitreal Injections
KW - Macula Lutea/pathology
KW - Vascular Endothelial Growth Factor A/antagonists & inhibitors
KW - Aged, 80 and over
UR - http://www.scopus.com/inward/record.url?scp=85187290273&partnerID=8YFLogxK
UR - https://pearl.plymouth.ac.uk/context/pms-research/article/2120/viewcontent/1_s2.0_S2468653023006747_main.pdf
U2 - 10.1016/j.oret.2023.12.012
DO - 10.1016/j.oret.2023.12.012
M3 - Article
C2 - 38171416
SN - 2468-6530
VL - 8
SP - 545
EP - 552
JO - Ophthalmology Retina
JF - Ophthalmology Retina
IS - 6
ER -